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Abstract
Approximately, twenty years ago, the Rare
Cancer Network (RCN) was formed in
Lausanne, Switzerland, to support the study of
rare malignancies. The RCN has grown over
the years and now includes 130 investigators
from twenty-four nations on six continents.
The network held its first international sympo-
sium in Nice, France, on March 21-22, 2014.
The proceedings of that meeting are presented
in two companion papers. This manuscript
reviews the history of the growth of the RCN
and contains the abstracts of fourteen oral pre-
sentations made at the meeting of prior RCN
studies. From 1993 to 2014, 74 RCN studies
have been initiated, of which 54 were complet-
ed, 10 are in progress or under analysis, and 9
were stopped due to poor accrual. Forty-four
peer reviewed publications have been written
on behalf of the RCN. 
Introduction
Approximately twenty years ago, the Rare
Cancer Network, (RCN) was formed by
Professors Rene-Olivier Mirimanoff and
Mahmut Ozsahin (ROM and MO) in Lausanne,
Switzerland. The RCN has grown substantially
over the years and includes investigators from
twenty-four nations on six continents. The net-
work held its first international symposium in
Nice, France, on March 21-22, 2014. The pro-
ceedings of that meeting are presented in two
companion papers. The first, this manuscript,
reviews the history of the RCN and selected
works published to date. The second manu-
script will review ongoing investigations and
the future vision of the RCN membership for
rare cancer research.
History and the Rare CancerNetwork 
The original idea to create the Rare Cancer
Network in the 1990’s stems from the observa-
tion that case reports and small series of
patients with a rare type of tumor were not
very contributory to medical knowledge or even
provided contradictory conclusions. For exam-
ple, Morgan et al. at Institut Gustave Roussy in
a series of 14 patients with gonadotropin-pro-
ducing seminoma (HCGs), found that this
uncommon subtype of seminoma had a worse
prognosis than typical seminoma, whereas
Mirimanoff et al. at Massachusetts General
Hospital found exactly the opposite in their
analysis of 10 HCGs cases.1,2 This difference
was likely to be due to selection bias and other
flaws inherent in small series of patients.
Differences in staging procedures, final stage,
histology (pure versus mixed tumors), and
treatments could have been responsible for the
discrepancy between the two papers. To avoid
at least part of these biases, a new study was
initiated and aimed at gathering a larger num-
ber of patients. Thanks to the collaboration
between 10 academic centers from France and
Switzerland, data on 123 consecutive patients
with HCGs could be collected, and this was the
largest published series at this time.3 Results
unequivocally confirmed that HCGs had an
excellent prognosis at all stages and at all HCG
levels, which was quite comparable with the
prognosis of the more common non-HCG
secreting seminomas. This positive experi-
ence stimulated two of us (ROM and MO) to
create an international network, the RCN, to
initiate large retrospective studies on rare can-
cers, knowing that the prospective accrual of
patients with rare tumor types in experimental
trials would be extremely slow and difficult.
The initial structure of the group was quite
simple and light, with no meetings and only
electronic exchange of information and data
collection. However rules for participation
were quite strict in regards to membership,
study initiation, data collection, data analyses,
ethical standards, and publication rules.
Although there is no simple and unique defini-
tion of what is a rare cancer, studies of the
RCN were to include either patients suffering
from a cancer with a rare pathological type
(example Merkel cell carcinoma), or cancers
with a more common pathological type but in a
rare site [example extranodal non-Hodgkin’s
lymphoma (NHL)], or at a rare age (example
nasopharyngeal carcinoma in children), or
with a rare sex presentation (example male
breast cancer), or with unusual biological
characteristics (example HCGs). The objec-
tives of these studies were to acquire a better
knowledge of the clinical profile of rare types
of cancers (and therefore to select the most
appropriate investigations), to better define
the respective role of surgery, radiotherapy and
chemotherapy or their combination, to esti-
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mate more precisely the classical outcomes
(overall survival, disease-free survival, local
and distant disease-free survival), to look at
the patterns of failures and finally to review all
potential prognostic factors in performing uni-
variate and multivariate analyses. Over the
years, a number of investigators joined the
RCN. Currently the network has approximately
130 members in 70 institutions from 24 coun-
tries on 6 continents. From 1993 to 2014, 74
RCN studies have been initiated, of which 54
were completed, 10 are in progress or under
analysis, and 9 were stopped due to poor accru-
al. Currently 14 new study proposals are being
discussed. To date, 46 articles have been pub-
lished on behalf of the RCN. Their publication
frequency over time is shown in Figure 1. The
majority were published in leading cancer or
radiotherapy journals like the International
Journal of Radiation Oncology Biology Physics
(18), Radiotherapy and Oncology (4), Annals
of Oncology (2), BMC Cancer (2), Lancet
Oncology (1), European Journal of Cancer (1)
and Rare Tumors (3) as shown in Table 1. The
total number of patients included in published
studies is 3812, with a median number of
patients per study of 81 (range 9-443). See
Table 2 for a summary. Representatives of
some of the best studies of the network are
presented later in this article. Some RCN
series are the largest worldwide or the second
largest in their field, like for example those on
phyllodes tumors of the breast (443 patients),
solitary plasmocytoma (258 patients), pedi-
atric nasopharyngeal tumors (165 patients),
mandibular osteosarcoma (111 patients), pri-
mary bone lymphoma (116 patients), and sev-
eral other disease sites. See Table 3 for a sum-
mary of the five largest studies published.4-8 Of
all completed studies, the most frequent tumor
sites or tissues were the CNS/eye (8), the soft
tissue/bone (8), the male genito-urinary sys-
tem (7), the head and neck (6), the breast (6),
the female genito-urinary system (4) and the
remainder in other various sites, as shown in
Figure 2. Of interest, there were 8 published
papers on extra-nodal NHL, the majority of
these were amongst the largest in the litera-
ture. In most of them the role of radiotherapy
and/or combined chemo-radiotherapy was
demonstrated on univariate or multivariate
analyses. The founding members of the RCN
also published a textbook in 2010 focusing on
the science and treatment of adult rare
tumors.9
In summary, RCN, a virtual but well organ-
ized group has already contributed to better
define the disease profile, the outcomes, and
therapeutic and prognostic factors in a good
number of rare cancers, thanks to the active
participation of its members. However,
although rare cancers are by definition very
infrequent, there are many different types and
there is a clear need to perform many other
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Figure 1. Publication frequency over time for the Rare Cancer Network in peer reviewed,
academic journals, 1999-2013.
Figure 2. Distribution of sites of malignant diseases studied in Rare Cancer Network by
number of studies per site.
Table 1. Overview of frequency of published papers of the Rare Cancer Network by jour-
nal.
Journal                                      N. papers                  Journal                    N. papers
Int J Rad Onc Biol Phys                                18                      Rep Pract Onc Rad                          1
Radioth Oncol                                                 4                               Gyn Oncol                                  1
Rare Tumors                                                    3                                Oral Surg                                  1
Ann Oncol                                                        2                               Rad Oncol                                  1
Bull Cancer                                                      2                          Am J Clin Oncol                             1
Cancer Rad                                                      2                          Clin Trans Oncol                            1
Crit Rev Onc Hem                                          2                             Act Orth Bel                                1
BMC Cancer                                                    2                                  Dis Oes                                    1
Lancet Oncol                                                   1                               Onkologie                                  1
Euro J Cancer                                                 1                              Bull Cancer                                 1
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studies on the large remaining number of
these orphan diseases.
The Rare Cancer Network and growth of the internet 
Rare cancers are difficult to study due to
their infrequency. Clinical trials, even in coop-
erative groups, are challenging due to the low
accrual rates over time. Studies performed
using population based data sources, such as
the SEER-Medicare database, can provide sta-
tistical power, but have not in the past con-
tained sufficient details to draw meaningful
conclusions on individual treatment modali-
ties and prognostic factors.10
The Rare Cancer Network came into being
at the time the internet was evolving from a
specialist tool used in research into a modus
for everyday communication. In the early
1990’s, medical research took place in silos
based on location, nationality, specialty, and
language to a degree much greater than the
current day. Rare tumor research was largely
confined to the largest medical institutions
that could report on single institution clinical
experiences. Global communication was slow
and expensive. The emergence of email and
the World Wide Web provided an ideal platform
for collaborations between researchers inter-
ested in rare disease. Email provided a cheap
and rapid means for the leadership of the Rare
Cancer Network to rapidly connect researchers
around the globe on an ad hoc basis rather
than through existing formal channels of com-
munication. Although common at the time of
this publication, such collaborations were still
novel in the 1990’s and contributed greatly to
the early success of the network.
Summary of past researchstudies presented at theSymposium
Pediatric nasopharyngeal cancer(E. Ozyar)
Pediatric nasopharyngeal cancer (NPC) is
mainly seen in Mediterranean countries and
constitutes 8-18% of all NPC patients in this
region. In contrast to adult NPC, the optimal
chemo-radiotherapy sequence and radiothera-
py dose has not been established yet in the
pediatric population. The RCN pediatric NPC
study enrolled 165 cases from 16 centers and
majority patients were from Mediterranean
region. This study is still the largest series in
the literature.8
Adenosquamous carcinoma of head and neck (U. Schick)
Adenosquamous carcinoma of the head and
neck is a rare malignancy with fewer than 100
cases reported in the literature. Classically,
adenosquamous carcinoma has been
described as having an aggressive behavior
and an associated with poor prognosis.
However, given the rarity of the disease, nei-
ther the prognostic factors nor the optimal
management strategy, especially regarding
adjuvant treatment are well characterized.
Within the RCN, we collected interesting data
from an heterogeneous group of patients. We
showed that, despite high rates of locoregional
and distant recurrence, patients with early
stage disease that are managed with combined
modality treatment can achieve favorable out-
comes.11Olfactory neuroblastoma (B. Pehlivan)
Olfactory neuroblastoma (ONB) or esthe-
sioneuroblastoma is a rare malignant disease
of the olfactory neuroepithelium. It constitutes
only 3% of all intranasal neoplasms, and can be
observed in both children and adults. Its inci-
dence peaks between either 11 and 20 years or
51 and 60 years. In this multicenter retrospec-
tive RCN study including 13 European and
North American centers, 77 patients were
enrolled. Being one of the largest studies in
the literature, it concluded that ONB treated
with R0 or R1 surgical resection followed by at
least 54-Gy postoperative radiotherapy has the
best outcome.12Mucosal melanoma of the aerodi-gestive tract (M. Krengli)
Mucosal melanoma of the upper aero-diges-
tive tract is a rare tumor, representing less
than 2% of all melanoma cases. The optimal
treatment strategy, including the role of radio-
therapy, has still to be defined. The RCN study
analyzed 74 patients, most of them (57%) in
postoperative setting. Local control was
improved by postoperative radiotherapy and
initial stage and melanosis at diagnosis were
favorable prognostic factors. A subsequent lit-
erature review confirmed that radiotherapy
plays a role in the treatment of mucosal
melanoma of the upper aero-digestive tract
although the dose and fractionation schemes
still require further investigation.13,14Sarcoma of the uterus (A. Franzetti)
Primary Uterine Leiomyosarcoma (ULMS)
is a rare type of cancer with a definite patho-
logical identity among the five different cate-
gories of uterine sarcoma. ULMS remains a
tumor with poor prognosis. Uterine sarcomas
represent 2-6% of all malignant uterine
tumors. Each group of these tumors exhibits a
different pattern of spread, prognostic factors
and likely, different responses to treatments.
Considering the rare incidence of these
tumors and their different subgroups is very
difficult to collect a sufficiently number of
patients. In this multi-center retrospective
RCN study 110 patients affected by primary
ULMS were collected from 19 member institu-
tions and analyzed. The study was aimed at
assessing and establishing prognostic and
therapeutic factors in patients with primary
ULMS most of them treated with surgery and
adjuvant radiotherapy. The poor overall prog-
nosis of this rare and aggressive disease indi-
cates a strong need to evaluate new therapeu-
tic approaches as well as its sequence. The role
of radiotherapy needs to be assessed in the
light of new high-precision techniques.
Publication of this manuscript is pending.
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Table 2. Overview of studies published by the Rare Cancer Network.
Category                                                                                             N. papers
Studies conducted from 1993-2014                                                                                    73
     Completed studies                                                                                                            54
     Studies in progress                                                                                                           10
     Studies discontinued                                                                                                         9
Published articles                                                                                                                  46
Abstract publication only                                                                                                     >18
Table 3. The 5 largest studies of the Rare Cancer Network.
Tumor Type                    N. Patients                      Journal                      Year              Ref.
Phyllodes breast                              443                        Int J Rad Onc Biol Phys                2008                     4
DCIS young patients                       373                                  Lancet Oncol                          2006                     5
Plasmacytoma                                   258                         Int J Rad Onc Biol Phys                2006                     6
Merkel cell                                       180                         Int J Rad Onc Biol Phys                2011                     7
Pediatric NPC                                   165                                 Radioth Oncol                         2006                     8
DCIS, ductal carcinoma in situ; NPC, nasopharyngeal cancer.
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Solitary plasmocytoma (M. Ozsahin)
Solitary plasmacytoma (SP) is defined as a
proliferation of monoclonal plasma cells without
evidence of significant bone-marrow plasma-
cell infiltration, and constitutes about 5% of
cases of plasma-cell myeloma. SP has two sepa-
rate entities originating from either bone or
extramedullary soft tissues. Its treatment con-
sists of definitive radiotherapy (RT) but there
are no conclusive data on the optimal radiation
dose. This retrospective RCN study being the
largest reported in the literature, enrolled 258
patients (206 bone and 52 extramedullary SP)
from 19 European and North American centers,
and concluded that progression to multiple
myeloma is the main problem. Patients with
extramedullary SP had the best outcome, espe-
cially when treated with moderate-dose RT (≥30
Gy), even for larger tumors.6Non-Hodgkins lymphoma of bone(L. Cai)
Primary bone lymphoma (PBL) is a rare
entity of non-Hodgkin’s lymphoma accounting
for 5% of primary malignant bone tumors. In
our comprehensive review of 136 patients with
PBL, we identified 116 patients with single
bone lesions and found that adequate radio-
therapy and chemotherapy were essential
regarding the outcome. The remaining 20
cases were excluded from our analysis because
of either late stages (III and IV) or because of
multiple bone lesions at the outset. Thus the 8
cases in this report represent a subset with
multiple bone lesions. We wished to clarify the
profile and outcome of those particular cases
of PBL compared to PBL with single bone
involvement. These 8 cases of multiple bone
involved PBL had comparable characteristics
as early stage PBL. We found that PBL with
multiple bone involvement is not related with a
poor prognosis. Combined chemoradiotherapy
does benefit for these patients, especially
enough cycles of chemotherapy.15Squamous cell carcinoma of thebreast (L. Scandolaro)
Breast squamous cell carcinoma (BSCC) is
a rare disease, counted within metaplastic
breast cancers, whose diagnosis follows strict
criteria. The RCN collected 35 patients with
tumors of large size (mean 38 mm; range 10-
180 mm) and negative hormone receptors. A
combination of surgery and radiotherapy is the
best therapeutic option. The most favorable
chemotherapeutic approach seems to be the
combination of cisplatin and 5-Fluorouracil in
a neoadjuvant setting. Progression occurs
mainly in the first 4 years, particularly with
bone and lungs metastases. After this period,
further metastatic progression was not
observed. To best of our knowledge, this is the
second largest experience concerning this dis-
ease after the largest report of MD Anderson-
Texas.16Carcinosarcoma of the uterus (H.J. Vees)
Uterine carcinosarcomas (UCS) are dedif-
ferentiated carcinomas comprised of carcino-
matous and sarcomatous elements. According
to the National Comprehensive Cancer
Network, they should be considered as carcino-
mas. There is no consensus concerning the
optimal therapeutic management of UCS due
to its rarity. A multi-institutional RCN study
collected 124 patients in between 1987 and
2007. All patients underwent surgery and the
majority received external beam radiotherapy
with and without brachytherapy. The results of
this investigation have been submitted for
publication at this time.Phyllode tumor of the breast (Y. Belkacemi)
Phyllodes tumors (PT) are rare fibroepithe-
lial neoplasms of the breast representing 1% of
all breast cancers. The distinction between
malignant and non-malignant forms of this
tumors has been widely debated. In 1982, the
World Health Organization (WHO) proposed a
classification, which supports the concept of a
continuum between three different histologic
types of PT: benign, borderline or intermedi-
ate, and malignant. Surgery is the standard of
care for first-line treatment of PT. The limited
numbers of patients in the reported studies
has prevented any consistent conclusion about
prognostic factors or the role of RT in the past.
The RCN study is one of the largest reports in
the literature, with 443 women treated in 17
worldwide centers. Since RCN publication,
there has been 8 important published series
including one meta-analysis (n=5530) and 2
registry reports from SEER (n=1035) and
California (n=752).4Primary pineal tumors (S. Villa)
Combined modality therapy (surgery, radio-
therapy, and chemotherapy) for primary pineal
tumors have demonstrated good overall sur-
vival in the modern era. Age, dissemination at
diagnosis and, probably, histological subtypes
influenced survival in our series. The preva-
lence of chronic toxicity suggests that new
strategies in radiotherapy and chemotherapy
are advisable. Further studies are needed to
really define different diseases of PPTs con-
cerning histological subtypes and individual-
ized therapeutic strategies.17Duct cell carcinoma of the prostate(S. Igdem)
Prostatic duct adenocarcinoma (PDA) is a
rare variant of prostate cancer representing
about 1% of all prostate cancer cases. We col-
lected the clinical data of 31 patients from 6
member institutions of the RCN. Our results
suggest that PDA is a cancer with a behavior
similar to that of high Gleason grade acinar
carcinoma. Good local control can be achieved
by either radiation or surgery. Postoperative
radiotherapy seems to work as an adjuvant or
salvage treatment.18Langerhans cell histiocytosis (B. Atalar)
Langerhans Cell Histiocytosis (LCH) is an
uncommon benign bone tumour typically seen
in children. LCH of the bone in adults has been
reported in isolated cases. Thirty patients from
five RCN centers were analyzed to determine
the outcome of different treatment approaches
and to determine the role of radiotherapy in
adult LCH of bones. The results of this study
suggest that recurrence rates were significant-
ly lower in patients who were treated with both
surgery and RT. Surgery plays the primary role
in the treatment of adult LCH of the bone;
radiotherapy should be considered in the adju-
vant setting and for palliation.19Erdheim-chester disease (R. Miller)
Erdheim-Chester disease (ECD) is a rare
non-Langerhans histiocytoses. Histiocytic
infiltration of bones and other organs second-
ary to ECD can lead to pain, particularly in long
bones of the appendicular skeleton, as well as
mass associated symptoms in the brain or
orbits. The RCN conducted a small review of
symptom palliation that found that low dose RT
was associated with excellent short term pain
relief, but that symptoms typically recurred at a
later date, reflecting the systemic nature of
this disease.20
Rare Cancer Network studiesnot presented at theSymposium
A complete summary of publications of the
Rare Cancer Network through the year 2012
containing details on studies not presented at
this meeting is available in a prior
publication.21
Conclusions
The Rare Cancer Network has made signifi-
cant contributions to the understanding of rare
cancer behavior and treatment as outlined in
the reports above and elsewhere. Beginning as
a modest initiative to better understand prog-
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nostic factors in testicular cancers, the Rare
Cancer Network has now grown to include
researchers across the globe.
On-going and planned studies will be dis-
cussed in the second manuscript of proceed-
ings from the international symposium. As
also noted above, the rise of the Rare Cancer
Network was facilitated by technological
changes that permitted rapid and cheap com-
munication globally in ways not possible
before the emergence of the internet. Further
evolutions in technology, most notably the new
prominence of big analytics in research utiliz-
ing electronic medical records and the rapidly
falling price of genetic profiling, also present
new opportunities and challenges in rare can-
cer study. The future vision of the RCN to
advances its mission through these mecha-
nisms will be discussed in the second proceed-
ings paper. 
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